Elvium Life Sciences

Elvium Life Sciences is a Canadian pharmaceutical company headquartered in Pickering, Ontario, that specializes in treatments for Attention Deficit Hyperactivity Disorder (ADHD). Launched in 2018 as an affiliate of Purdue Pharma (Canada), the company was established to provide a dedicated focus on the ADHD therapeutic area. Its flagship product is Foquest, a controlled-release methylphenidate hydrochloride capsule designed for patients aged six and older. Elvium leverages advanced drug delivery technologies to offer long-acting treatment options that address the needs of patients throughout the day. The company is committed to supporting the ADHD community through education and innovative pharmacological solutions. As a private entity, it operates as a key player in the Canadian neurodevelopmental health market.